Trelleborg Receives Patent for Dartex Zoned Coatings

The Trelleborg Engineered Coated Fabrics manufacturing facility in Nottingham, England, has received a patent for its Dartex Zoned Coatings®.

Dartex Zoned Coatings® uniquely offer the ability to ‘zone’ different polyurethane coatings on support surface covers used in healthcare and medical applications, allowing a single fabric to perform multiple functions. Inventors of patent number US 11,499,265 B2 are Richard Haxby, Technical Director and Ilias Alexandrakis, Senior Development Project Manager.

Haxby says: “Trelleborg has a long history of developing intellectual property and understands the value of investing in research to help drive innovation in its chosen industries, including healthcare and medical. Dartex Zoned Coatings® technology is revolutionary, making it possible for medical device manufacturers to develop the ultimate support surfaces.”

Alexandrakis, adds: “This is an exciting advancement for the industry. It will mean that medical device manufacturers can streamline their production processes, potentially saving money and bringing products to market more quickly.”

Using patent-pending manufacturing methods, Dartex Zoned Coatings® allows zoning of a support surface cover so that a single cover can have multiple physical and stretch properties across different zones without joins, welds or seams. They incorporate trusted Dartex® polyurethane coating technology from Trelleborg for patient comfort and quality.

The coatings are suitable for multiple healthcare and medical applications, including mattress covers (tops and encasements), moving and handling, positioning devices, specialist medical furniture, theatre tables, trollies and stretchers. Mattress covers can be zoned in harmony with the mattress core.

Find out more about Trelleborg’s Dartex Zoned Coatings® here: https://www.trelleborg.com/engineered-coated-fabrics/industries/healthcare-and-medical/healthcare-and-medical-product-range/dartex-zoned-coatings

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”